Teresa Carvalho, MS,  science writer—

Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.

Articles by Teresa Carvalho

First Volunteer Dosed in Phase 1 Trial of SION-638

The first participant has been dosed in a Phase 1 clinical trial evaluating Sionna Therapeutics‘ SION-638, an investigational oral treatment for cystic fibrosis (CF). The trial aims to assess the safety and pharmacokinetics — the movement into, through, and out of the body — of SION-638 in healthy volunteers.

Beam CF Youth Program Launched for Children With CF

CF Youth, a new exercise program created by Beam for children living with cystic fibrosis (CF), was launched on the company’s online platform. The initiative, created in collaboration with CF Yogi and Johns Hopkins Cystic Fibrosis Center, can be accessed by caregivers and healthcare providers. Regular exercise has been…

#RAREis Representation Program Promotes Equity, Diversity

Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.